← Leaderboards
Wenyi Wei
Brigham And Women'S Hospital
$20,822,884
Attributed
$25,465,464
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,465,464 · 10
By mechanism
R01$20,275,658 · 9
R35$5,189,806 · 1
Top collaborators
- Alex Toker6 shared
- Edwin K Silverman4 shared
- Anny Xiaobo Zhou4 shared
- David K. Simon2 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Hamid Band$15,640,616
- Craig P Hersh$16,648,360
- Jakub Godlewski$1,752,079
- Anny Xiaobo Zhou$14,633,236
- Edwin K Silverman$89,199,838
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularMediatingPathway InteractionsSignal TransductionMalignant NeoplasmsInsightProteinsOncogenicUbiquitinationTumorIn VivoUbiquitin-Protein LigaseComplexBaseTumorigenesisRegulationBiochemicalInhibitor/AntagonistSignal PathwayCellsCell Cycle RegulationCell CycleAntineoplastic AgentsPhosphorylation
Grant awards (52)
Deciphering the physiological role and interplay between ubiquitination and phosphorylation pathways to guide targeted cancer therapies$1,042,944
R35 · FY2025 · CA · contact PI
Targeting the FBXW7/PGC1 Pathway as a Therapeutic Strategy for Parkinson's Disease$590,222
R01 · FY2025 · NS
Deciphering the physiological role and interplay between ubiquitination and phosphorylation pathways to guide targeted cancer therapies$997,500
R35 · FY2024 · CA · contact PI
Identifying Protein-Protein Network Interactions between COPD Susceptibility Genes$775,224
R01 · FY2024 · HL
Targeting the FBXW7/PGC1 Pathway as a Therapeutic Strategy for Parkinson's Disease$665,971
R01 · FY2024 · NS
Deciphering the physiological role and interplay between ubiquitination and phosphorylation pathways to guide targeted cancer therapies$795,316
R35 · FY2023 · CA · contact PI
Identifying Protein-Protein Network Interactions between COPD Susceptibility Genes$794,713
R01 · FY2023 · HL
Integrative Characterization on the function of COPD GWAS gene, HHIP$655,509
R01 · FY2023 · HL
Novel regulation of PI3K/Akt to direct targeted breast cancer therapies$407,313
R01 · FY2023 · CA · contact PI
Deciphering the physiological role and interplay between ubiquitination and phosphorylation pathways to guide targeted cancer therapies$1,025,412
R35 · FY2022 · CA · contact PI
Identifying Protein-Protein Network Interactions between COPD Susceptibility Genes$794,713
R01 · FY2022 · HL
Integrative Characterization on the function of COPD GWAS gene, HHIP$655,509
R01 · FY2022 · HL
Novel regulation of PI3K/Akt to direct targeted breast cancer therapies$407,313
R01 · FY2022 · CA · contact PI
Deciphering the physiological role and interplay between ubiquitination and phosphorylation pathways to guide targeted cancer therapies$1,050,000
R35 · FY2021 · CA · contact PI
Identifying Protein-Protein Network Interactions between COPD Susceptibility Genes$812,488
R01 · FY2021 · HL
Integrative Characterization on the function of COPD GWAS gene, HHIP$655,509
R01 · FY2021 · HL
Novel regulation of PI3K/Akt to direct targeted breast cancer therapies$415,625
R01 · FY2021 · CA · contact PI
Integrative Characterization on the function of COPD GWAS gene, HHIP$675,259
R01 · FY2020 · HL
Novel regulation of PI3K/Akt to direct targeted breast cancer therapies$415,625
R01 · FY2020 · CA · contact PI
Characterizing the signaling pathways that regulate Skp2 oncogenic function$395,738
R01 · FY2020 · CA · contact PI
Targeting the APC/Cdc20 E3 ubiquitin ligase for chemoradiation sensitization$383,385
R01 · FY2020 · CA · contact PI
Functional analysis of a tissue context-dependent role for beta-TRCP in lipid metabolism and tumorigenesis$374,063
R01 · FY2020 · CA · contact PI
Deciphering the physiological role and interplay between ubiquitination and phosphorylation pathways to guide targeted cancer therapies$278,634
R35 · FY2020 · CA · contact PI
Novel regulation of PI3K/Akt to direct targeted breast cancer therapies$415,625
R01 · FY2019 · CA
Characterizing the signaling pathways that regulate Skp2 oncogenic function$383,865
R01 · FY2019 · CA · contact PI
Targeting the APC/Cdc20 E3 ubiquitin ligase for chemoradiation sensitization$371,883
R01 · FY2019 · CA · contact PI
Functional analysis of a tissue context-dependent role for beta-TRCP in lipid metabolism and tumorigenesis$362,840
R01 · FY2019 · CA · contact PI
Characterizing the signaling pathways that regulate Skp2 oncogenic function$395,738
R01 · FY2018 · CA · contact PI
Targeting the APC/Cdc20 E3 ubiquitin ligase for chemoradiation sensitization$383,385
R01 · FY2018 · CA · contact PI
Functional analysis of a tissue context-dependent role for beta-TRCP in lipid metabolism and tumorigenesis$374,063
R01 · FY2018 · CA · contact PI
Interplay between Cdh1 and major regulatory pathways in human cancer$334,950
R01 · FY2018 · GM · contact PI
Characterizing the signaling pathways that regulate Skp2 oncogenic function$395,738
R01 · FY2017 · CA · contact PI
Targeting the APC/Cdc20 E3 ubiquitin ligase for chemoradiation sensitization$383,385
R01 · FY2017 · CA · contact PI
Novel regulation of PI3K/Akt to direct targeted breast cancer therapies$361,050
R01 · FY2017 · CA
Interplay between Cdh1 and major regulatory pathways in human cancer$334,950
R01 · FY2017 · GM · contact PI
Targeting the APC/Cdc20 E3 ubiquitin ligase for chemoradiation sensitization$401,635
R01 · FY2016 · CA · contact PI
Characterizing the signaling pathways that regulate Skp2 oncogenic function$395,738
R01 · FY2016 · CA · contact PI
Novel regulation of PI3K/Akt to direct targeted breast cancer therapies$361,050
R01 · FY2016 · CA
Interplay between Cdh1 and major regulatory pathways in human cancer$334,950
R01 · FY2016 · GM · contact PI
Novel regulation of PI3K/Akt to direct targeted breast cancer therapies$361,050
R01 · FY2015 · CA
Interplay between Cdh1 and major regulatory pathways in human cancer$334,950
R01 · FY2015 · GM · contact PI
Functional analysis of beta-TRCP in cell cycle control and DNA damage response$328,425
R01 · FY2015 · GM · contact PI
Novel regulation of PI3K/Akt to direct targeted breast cancer therapies$350,219
R01 · FY2014 · CA
Functional analysis of beta-TRCP in cell cycle control and DNA damage response$328,425
R01 · FY2014 · GM · contact PI
Novel regulation of PI3K/Akt to direct targeted breast cancer therapies$361,050
R01 · FY2013 · CA
Interplay between Cdh1 and major regulatory pathways in human cancer$329,137
R01 · FY2013 · GM · contact PI
Functional analysis of beta-TRCP in cell cycle control and DNA damage response$316,930
R01 · FY2013 · GM · contact PI
Interplay between Cdh1 and major regulatory pathways in human cancer$341,075
R01 · FY2012 · GM · contact PI
Functional analysis of beta-TRCP in cell cycle control and DNA damage response$328,425
R01 · FY2012 · GM · contact PI
Interplay between Cdh1 and major regulatory pathways in human cancer$341,075
R01 · FY2011 · GM · contact PI
Interplay between Cdh1 and major regulatory pathways in human cancer$344,273
R01 · FY2010 · GM · contact PI
Interplay between Cdh1 and major regulatory pathways in human cancer$345,600
R01 · FY2009 · GM · contact PI